Joaquim Bellmunt
Beth Israel Deaconess Medical Center
CancerInternal medicineUrologySurgeryOncologyCystectomyChemotherapyRenal cell carcinomaCarcinomaCisplatinSunitinibPembrolizumabProstate cancerBladder cancerDocetaxelMetastatic Urothelial CarcinomaIn patientUrothelial carcinomaCancer researchClinical trialMedicine
797Publications
87H-index
34.2kCitations
Publications 794
Newest
#1Thomas PowlesH-Index: 84
#2Daniel P. PetrylakH-Index: 48
Last. Jeanny B. Aragon-ChingH-Index: 24
view all 16 authors...
INTRODUCTION AND OBJECTIVE:In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance+best supportive care (BSC) significantly prolonged overall survival (OS) vs BSC alone in pa...
Source
#1Petros GrivasH-Index: 24
#2Se Hoon ParkH-Index: 53
Last. Jing WangH-Index: 106
view all 15 authors...
INTRODUCTION AND OBJECTIVE:Avelumab first-line (1L) maintenance is approved in various countries for patients (pts) with advanced urothelial carcinoma (UC) that has not progressed with 1L platinum-...
Source
#1Risa L. Wong (Fred Hutchinson Cancer Research Center)H-Index: 1
#2Lorin Ferris (UW: University of Washington)
Last. Ugo De GiorgiH-Index: 55
view all 19 authors...
BACKGROUND Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes with subsequent platinum-based chemotherapy (sPBC) versus subsequent non-platinum-based chemotherapy (sNPBC). MATERIALS AND METHODS Patients from 27 international centers in the Retrospective International Study of Cancers of the Urothelium (RISC) w...
Source
#1Thomas Powles (QMUL: Queen Mary University of London)H-Index: 84
#2Zoe June Assaf (Genentech)H-Index: 11
Last. Jürgen E. Gschwend (TUM: Technische Universität München)H-Index: 57
view all 27 authors...
Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse1. We evaluated outcomes in 581 patients who had undergone surgery and were evaluable for ctDNA from a randomized phase III trial of adjuvant atezolizumab versus observation in operable urothelial cancer. This trial did not reach its efficacy ...
2 CitationsSource
#1Joaquim Bellmunt (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 87
Source
#1Joaquim Bellmunt (Harvard University)H-Index: 87
#2Emilio EstebanH-Index: 22
Last. Alfonso Calvo (University of Navarra)H-Index: 37
view all 13 authors...
Abstract Pazopanib is an oral angiogenesis tyrosine kinase inhibitor (TKI) recommended in metastatic renal cell carcinoma (mRCC) for treatment-naive patients or those experiencing cytokine failure. We conducted a phase 2, open-label, single-arm study in ten Spanish centres among mRCC patients whose disease progressed on first-line TKI. Patients received pazopanib until disease progression, death, or unacceptable toxicity. Twenty-seven patients were included (median age 62 yr, 51.9% male). The ob...
1 CitationsSource
1 CitationsSource
Source
#1Ariana L. Santopietro (BIDMC: Beth Israel Deaconess Medical Center)
#2David J. Einstein (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
Last. Joaquim Bellmunt (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 87
view all 3 authors...
INTRODUCTION Urothelial carcinoma (UC) is the second most common malignancy of the genitourinary system in the US but mortality rate has not significantly improved despite advances in therapy. Over the past few years, the treatment landscape of non-muscle invasive, muscle-invasive and metastatic UC (mUC) has evolved with the advent of immunotherapy. AREAS COVERED This paper summarizes current data and ongoing research into the use of immune checkpoint inhibitors (ICIs) in various settings of UC,...
Source
Source